Lithostat Disease Interactions

Acetohydroxamic acid is primarily eliminated by the kidney and it is contraindicated in patients whose renal function is poor (serum creatinine more than 2.5 mg/dl and/or creatinine clearance less than 20 mL/min). Patients with less marked renal impairment may be at increased risk of toxicity associated with administration of acetohydroxamic acid and therapy should be administered cautiously and reduced dosage may be necessary.

The use of acetohydroxamic acid is a known inhibitor of DNA synthesis and also chelates metals - notably iron. Its bone marrow suppressant effect is probably related to its ability to inhibit DNA synthesis, but anemia could also be related to depletion of iron stores. Clinical monitoring of the platelet and white cell count is recommended in patients with bone marrow depression.

Abnormalities of liver function have not been reported to date. However, a chloro-benzene derivative of acetohydroxamic acid caused significant liver dysfunction in an unrelated study. Therefore, close monitoring of liver function is highly recommended in patients receiving AHA, especially in those with liver impairment.